Innoviva, Inc.
INVA
Positions held
Your positionsINVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Innoviva, Inc. operates in the biotechnology sector, which is poised for growth due to increasing demand for innovative therapies and treatments.
- Revenue increased by 22% compared to the prior quarter, reaching $120 million.
- Operating margin expanded to 42.5%, indicating improved efficiency in operations.
- The stock has a 'Strong Sell' signal with a score of -31.00, reflecting negative market sentiment.
- Net income for the latest quarter was -$83.42 million, highlighting financial challenges.
- Gross margin decreased to 75.8% from 84.1% in the prior quarter, indicating potential pricing pressures.
Fundamentals
| Market cap | $1.51B | Enterprise value | $1.26B | Trailing P/E | 4.88 | Forward P/E | 9.44 |
| PEG | 3.15 | Price / book | 1.23 | Beta | 0.38 | Dividend yield | 0.00% |
| Revenue growth | 19.3% | Earnings growth | — | Gross margin | 72.7% | Operating margin | 43.3% |
| Profit margin | 81.2% | ROE | 36.7% | ROA | 6.9% | Debt / equity | 0.27 |
| Current ratio | 16.01 | Free cash flow | $110.33M | Analyst recommendation | none | Mean target | $35.00 |
| 52w high | $25.15 | 52w low | $16.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $120M | $98.0M | $115M | $108M | $100M | — |
| Op margin | 42.5% | 38.9% | 34.0% | 32.1% | 48.6% | — |
| Net income | -$83.4M | $187M | $164M | $89.9M | $63.7M | — |
| Gross margin | 75.8% | 84.1% | 88.9% | 70.1% | 82.9% | — |
| Gross profit | $90.6M | $82.4M | $102M | $75.5M | $83.1M | — |
| Operating income | $50.9M | $38.2M | $39.0M | $34.6M | $48.8M | — |
- Revenue +22% vs prior quarter ($120M vs $98M).
- Gross margin 75.8% (was 84.1% prior quarter).
- Operating margin expanded to 42.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $411M | $359M | $310M | $331M | — |
| Op margin | 39.8% | 46.5% | 36.7% | 62.5% | — |
| Net income | $271M | $23.4M | $180M | $214M | — |
| Gross margin | 81.2% | 89.8% | 86.3% | 95.8% | — |
| Gross profit | $334M | $322M | $268M | $318M | — |
| Operating income | $164M | $167M | $114M | $207M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
2026-10-08 · INVA vs. MRK: Which Stock Is the Better Value Option?
2026-10-08 · 5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
2026-10-08 · Should Value Investors Buy Innoviva (INVA) Stock?
2026-09-30 · Oppenheimer Sees Massive Upside in 2 Stocks
2026-09-02 · Innoviva to Participate in Upcoming Investor Conferences
2026-08-07 · How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
2026-08-06 · Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
2026-08-05 · Innoviva: Q2 Earnings Snapshot
2026-08-05 · Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
2026-07-31 · AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
Price (daily)
Full chart · RSI · MACD · patterns